You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Harvard Business School
Merck
Moodys
Colorcon

Last Updated: February 26, 2020

DrugPatentWatch Database Preview

MOVIPREP Drug Profile


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Which patents cover Moviprep, and when can generic versions of Moviprep launch?

Moviprep is a drug marketed by Salix Pharms and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-four patent family members in twenty-two countries.

The generic ingredient in MOVIPREP is ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate profile page.

US ANDA Litigation and Generic Entry Outlook for Moviprep

Annual sales in 2017 were $8mm indicating the motivation for generic entry (peak sales were $33mm in 2009).

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Drug patent expirations by year for MOVIPREP
Drug Prices for MOVIPREP

See drug prices for MOVIPREP

Drug Sales Revenue Trends for MOVIPREP

See drug sales revenues for MOVIPREP

Recent Clinical Trials for MOVIPREP

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Russian Society of Colorectal SurgeonsN/A
Zealand University HospitalPhase 1
University of CopenhagenPhase 1

See all MOVIPREP clinical trials

Paragraph IV (Patent) Challenges for MOVIPREP

US Patents and Regulatory Information for MOVIPREP

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Salix Pharms MOVIPREP ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate FOR SOLUTION;ORAL 021881-001 Aug 2, 2006 AA RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Salix Pharms MOVIPREP ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate FOR SOLUTION;ORAL 021881-001 Aug 2, 2006 AA RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Moodys
Mallinckrodt
Colorcon
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.